Skip to main content

Table 1 Incidence and duration of acute dermatolymphangioadenitis (ADLA) in filariasis-endemic areas.

From: Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature

Study Annual incidence of ADLA in general population (per 1000) Annual incidence of ADLA in 'patients' (per patient) Mean duration of ADLA episode (days) Study site Notes
Bancroftian filariasis
Addiss 1999 [47] -- 2.1^ -- Haiti  
Alexander 1999 [42] 31 -- 16 Papua New Guinea Only cases with fever and ADLA in lower limb
Babu 2005 [48] 85.0 1.6† 3.9 Orissa, India  
Gasarasi 2000 [39] 33 -- 8.6 Tanzania  
Gyapong 1996 [40] 95.9 -- 5.1 Ghana  
Kanda 2004 [44] -- 1.5^ 10.6 Haiti  
Krishnamoorthy 1999 [45] -- 6.4‡ 4.1 Tamil Nadu, India  
Kron 2000 [52] -- -- 4.5 Philippines  
Mathieu 2005 [49] -- 2.3^ 7.3 Togo  
McPherson 2006 [50] -- 1.6^ -- Guyana  
Pani 1995 [21] -- 4.2^ 4.1 Tamil Nadu, India  
Ramaiah 1996 [41] 96.5 1.8† 3.6 Tamil Nadu, India  
Sabesen 1992 [46] 49.8 6.0^ 3.9 Tamil Nadu, India  
Brugian filariasis
Pani 1989 [51] -- 4.9^
7.6^
4.9
5.8
Kerala, India Stage 1 oedema
Stage 2 oedema
Rao 1982 [43] 371* -- 1.4 Kerala, India Only cases with fever
Sabesen 1992 [46] 41.4 5.4 4.9 Kerala, India  
Suma 2002 [32] -- 4.7^ -- Kerala, India Restricted to patients with ≥ 2 ADLA episodes.
  1. ^Lymphoedema patients only
  2. ‡ Lymphoedema and hydrocele patients
  3. † Among persons with one or more ADLA episodes in 1-year observation period
  4. *Calculated from 7 month follow-up